Hudson Bay Capital Management
WHWK

Hudson Bay Capital Management’s Whitehawk Therapeutics WHWK Stock Holding History

Hudson Bay Capital Management’s Portfolio WHWK Stock Details WHWK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-57,597
Closed -$199K – 1774
2026
Q1 		$199K Buy
+57,597
New +$180K ﹤0.01% 1107

Other funds holding WHWK

YF
Yu Fan $108M AUM 137.54% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return
QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
KCA
KVP Capital Advisors San Francisco, California $136M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Hudson Bay Capital Management's WHWK Position: Q2 2026 in Review

Hudson Bay Capital Management sold out of Whitehawk Therapeutics (WHWK) in Q2 2026, closing a stake of 57,597 shares — an estimated $199K sold.

Hudson Bay Capital Management first reported a position in WHWK in Q1 2026 and held it in 1 quarter. The position peaked at $199K in Q1 2026. 77 funds tracked by Wall St. Rank hold WHWK as of Q2 2026.

  • Hudson Bay Capital Management reported no remaining Whitehawk Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Hudson Bay Capital Management sold 57,597 Whitehawk Therapeutics shares in Q2 2026, an estimated $199K.
  • Hudson Bay Capital Management first reported a position in Whitehawk Therapeutics in Q1 2026 and held it in 1 quarter.
  • Hudson Bay Capital Management's Whitehawk Therapeutics position peaked at $199K in Q1 2026.
  • 77 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q2 2026.

Based on Hudson Bay Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.